These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 18573840
1. Factors associated with the risk of secondary progression in multiple sclerosis. Koch M, Uyttenboogaart M, van Harten A, De Keyser J. Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840 [Abstract] [Full Text] [Related]
2. Progression in familial and nonfamilial MS. Koch M, Uyttenboogaart M, Heerings M, Heersema D, Mostert J, De Keyser J. Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881 [Abstract] [Full Text] [Related]
5. Timing of birth and disease progression in multiple sclerosis. Koch M, De Keyser J, Tremlett H. Mult Scler; 2008 Jul; 14(6):793-8. PubMed ID: 18573829 [Abstract] [Full Text] [Related]
11. Multiple sclerosis in Pakistan. Wasay M, Ali S, Khatri IA, Hassan A, Asif M, Zakiullah N, Ahmed A, Malik A, Khealani B, Haq A, Fredrikson S. Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448 [Abstract] [Full Text] [Related]
12. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Glad SB, Nyland HI, Aarseth JH, Riise T, Myhr KM. Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821 [Abstract] [Full Text] [Related]
13. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population. El-Salem K, Khader Y. Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328 [Abstract] [Full Text] [Related]
14. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. D'hooghe MB, Haentjens P, Nagels G, Garmyn M, De Keyser J. Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096 [Abstract] [Full Text] [Related]
15. The natural history of primary progressive MS in British Columbia, Canada. Tremlett H, Paty D, Devonshire V. Neurology; 2005 Dec 27; 65(12):1919-23. PubMed ID: 16380613 [Abstract] [Full Text] [Related]
16. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. Lebrun C, Debouverie M, Jeannin S, Pittion-Vouyovitch S, Bayreuther C, Berthier F. Mult Scler; 2008 Aug 27; 14(7):933-9. PubMed ID: 18573824 [Abstract] [Full Text] [Related]
17. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Arch Neurol; 2009 Jan 27; 66(1):54-9. PubMed ID: 19139299 [Abstract] [Full Text] [Related]
18. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Veugelers PJ, Fisk JD, Brown MG, Stadnyk K, Sketris IS, Murray TJ, Bhan V. Mult Scler; 2009 Nov 27; 15(11):1286-94. PubMed ID: 19965558 [Abstract] [Full Text] [Related]
19. New natural history of interferon-beta-treated relapsing multiple sclerosis. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP. Ann Neurol; 2007 Apr 27; 61(4):300-6. PubMed ID: 17444502 [Abstract] [Full Text] [Related]
20. Cigarette smoking and progression in multiple sclerosis. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Neurology; 2007 Oct 09; 69(15):1515-20. PubMed ID: 17923613 [Abstract] [Full Text] [Related] Page: [Next] [New Search]